Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. More Details
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Nymox Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NYMX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NYMX underperformed the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: NYMX underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Nymox Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Type Of Shareholders Own The Most Number of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Shares?
4 months ago | Simply Wall StDoes The Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Share Price Fall With The Market?
5 months ago | Simply Wall StShould You Worry About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) CEO Pay?
Is Nymox Pharmaceutical undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Nymox Pharmaceutical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Nymox Pharmaceutical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of NYMX's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Nymox Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nymox Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of NYMX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Nymox Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NYMX is currently unprofitable.
Growing Profit Margin: NYMX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NYMX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare NYMX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: NYMX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Nymox Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NYMX is debt free.
Reducing Debt: NYMX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NYMX has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: NYMX is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.
What is Nymox Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NYMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NYMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NYMX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NYMX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NYMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Paul Averback (69 yo)
Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD2.32M) is above average for companies of similar size in the US market ($USD1.23M).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
|Founder||no data||US$2.32m||35.53% |
|General Counsel||14.33yrs||US$478.96k||0.20% |
|Lead Independent Director||no data||no data||no data|
|Independent Director||14.33yrs||no data||0.00052% |
|Independent Director||5.25yrs||no data||6.21% |
Experienced Board: NYMX's board of directors are seasoned and experienced ( 14.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Nymox Pharmaceutical Corporation's company bio, employee growth, exchange listings and data sources
- Name: Nymox Pharmaceutical Corporation
- Ticker: NYMX
- Exchange: NasdaqCM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$166.375m
- Shares outstanding: 76.32m
- Website: https://www.nymox.com
- Nymox Pharmaceutical Corporation
- Bay & Deveaux Streets
- 2nd Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NYMX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Nov 1997|
|NYM||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 1997|
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 23:34|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.